RLAY
Relay Therapeutics Inc

1,074
Loading...
Loading...
News
all
press releases
Investing in Oncology: 3 Cancer Stocks With Promising Pipelines
Relay Therapeutics, Pyxis Oncology and Allogene Therapeutics drive cancer innovation with pivotal trials and promising drug candidates.
Zacks·8d ago
News Placeholder
More News
News Placeholder
Relay Therapeutics (RLAY) Upgraded to Buy: What Does It Mean for the Stock?
Relay Therapeutics (RLAY) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Zacks·1mo ago
News Placeholder
Relay Therapeutics, Inc. (RLAY) Reports Q2 Loss, Beats Revenue Estimates
Relay Therapeutics (RLAY) delivered earnings and revenue surprises of +16.33% and +35.40%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·1mo ago
News Placeholder
RXRX vs. RLAY: Which Precision Biotech Stock is a Better Bet Now?
Recursion Pharmaceuticals and Relay Therapeutics both leverage their respective AI drug discovery platforms to potentially develop novel therapeutic candidates.
Zacks·2mo ago
News Placeholder
Can Recent Pipeline Expansion Efforts Offset RXRX's Earlier Losses?
Recursion Pharmaceuticals bets on REC-4881, cancer candidates and new hypophosphatasia therapy to rebuild momentum after key drug cuts rattled investors.
Zacks·2mo ago
News Placeholder
Can Recursion Pharmaceuticals' Strategic Deals Fuel Long-Term Growth?
RXRX is scaling its AI-driven drug discovery technology through billion-dollar pharma deals and strategic tech alliances.
Zacks·2mo ago
News Placeholder
Will RXRX's Shift in Pipeline Focus Help Restore Investor Faith?
Recursion Pharmaceuticals axes three drug programs after weak study data, but shifts focus to more promising candidates like REC-4881 to regain ground.
Zacks·2mo ago
News Placeholder
Can RXRX's AI-Based Approach Revolutionize the Drug Discovery Process?
Recursion Pharmaceuticals is transforming drug discovery with AI-driven RecursionOS, slashing costs and boosting development speed.
Zacks·3mo ago
News Placeholder
GameStop Reports Weak Sales, Joins Petco, Relay Therapeutics And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session
read more...
Benzinga·1y ago
News Placeholder
Key Takeaways From Relay Therapeutics Analyst Ratings
Latest Ratings for RLAY DateFirmActionFromTo Feb 2022BerenbergInitiates Coverage OnBuy Aug 2021HC Wainwright & Co.MaintainsBuy Jul 2021B of A SecuritiesInitiates Coverage OnBuy View More...
Benzinga·1y ago

Latest RLAY News

View

Advertisement. Remove ads.

Advertisement. Remove ads.